Logo

INDV

Indivior PLC

INDV

Indivior PLC • NASDAQ
$33.60 ▲ 0.36% (+0.12)
Market Cap $4.20 B
52w High $34.03
52w Low $7.62
Dividend Yield 0%
P/E 34.29
Volume 531.76K
Outstanding Shares 124.86M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $314M ▲ $187M ▲ $42M ▲ 13.376% ▲ $0.34 ▲ $51M ▼
Q2-2025 $302M ▲ $178M ▲ $18M ▼ 5.96% ▼ $0.14 ▼ $82M ▲
Q1-2025 $266M ▼ $156M ▼ $47M ▼ 17.669% ▼ $0.38 ▼ $76M ▼
Q4-2024 $299M ▼ $180M ▼ $59M ▲ 19.732% ▲ $0.45 ▲ $106M ▲
Q3-2024 $307M $234M $4M 1.303% $0.03 $22M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $445M ▼ $1.416B ▼ $1.623B ▼ $-207M ▲
Q2-2025 $510M ▲ $1.452B ▲ $1.71B ▲ $-258M ▲
Q1-2025 $373M ▲ $1.375B ▲ $1.661B ▼ $-286M ▲
Q4-2024 $320M ▲ $1.319B ▼ $1.667B ▲ $-348M ▼
Q3-2024 $318M $1.464B $1.631B $-167M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $42M ▲ $-41.961M ▼ $-20.434M ▼ $-2.997M ▲ $-65M ▼ $-62.399M ▼
Q2-2025 $18M ▼ $166.043M ▲ $-18.692M ▼ $-4.632M ▲ $138M ▲ $148.381M ▲
Q1-2025 $47M ▼ $75M ▲ $-5M ▼ $-17M ▼ $53M ▲ $70M ▲
Q4-2024 $66M ▲ $-5M ▼ $10M ▼ $27M ▲ $31M ▲ $-21M ▼
Q3-2024 $3M $8M $32M $-55M $-14M $-1M

Five-Year Company Overview

Income Statement

Income Statement Revenue has been steadily rising over the past five years, and the company earns a healthy margin on each dollar of sales. However, profits further down the income statement are thin and uneven. Operating profit has hovered close to break-even, and both EBITDA and net income have swung between loss and modest profit. This suggests a business with solid demand but still working through heavy costs, legal and strategic spending, and the challenge of turning strong sales into consistently strong earnings per share.

Balance Sheet

Balance Sheet The balance sheet shows a good-sized asset base but a noticeably smaller cash cushion than a few years ago. Debt levels are moderate and relatively stable, yet they matter more now because profitability is not robust. The most notable red flag is that shareholder equity has slipped into negative territory, likely reflecting past losses, legal provisions, or capital actions. This does not mean immediate distress, but it does signal a thinner financial buffer and less room for major shocks.

Cash Flow

Cash Flow Cash generation has been volatile. The company demonstrated that it can produce solid cash flow from operations in stronger years, but it has also had periods of weak or even negative cash flow. Free cash flow follows the same pattern: positive in good years, pressured in others. On the positive side, the business does not require heavy capital spending, which keeps investment needs relatively light. The key question is whether the company can stabilize its operating cash flows so that cash consistently follows its revenue growth.

Competitive Edge

Competitive Edge Indivior occupies a focused and defensible niche in addiction treatment, particularly for opioid use disorder. Its flagship long-acting injectable treatment, supported by a proprietary delivery technology and long-dated patents, gives it a meaningful edge and helps reduce direct generic pressure for many years. The firm benefits from strong relationships with specialists, established distribution in the U.S., and high patient retention. At the same time, it faces concentrated risk: dependence on a small number of key products and heavy exposure to U.S. policy, pricing, and reimbursement decisions, plus active competition from other long-acting addiction treatments.

Innovation and R&D

Innovation and R&D The company’s innovation strategy is centered on long-acting treatments and expanding beyond traditional opioid-based approaches. Its existing injectable platform has already changed how some patients are treated, and the pipeline aims to push this further with potential longer-interval injections, non-opioid mechanisms for opioid use disorder, and treatments for other addictions such as cannabis use disorder. This focus positions Indivior as a specialist in substance use disorders, but it also brings the usual drug development risks: clinical setbacks, regulatory delays, and uncertainty about future commercial uptake.

Summary

Indivior combines a clear therapeutic focus with a strong flagship product and meaningful technological and patent advantages. Revenue momentum and attractive gross margins show that its treatments are gaining traction and valued in the market. On the other hand, profits and cash flows remain uneven, and the shift to negative equity underscores that the financial foundation is still being rebuilt. The company’s future profile will depend on two things: its ability to keep growing and defending its core long-acting injectable franchise, and its success in turning that growth into steadier cash generation and a stronger balance sheet while advancing its next wave of addiction therapies.

NEWS

November 20, 2025 · 4:01 PM UTC

Indivior Concludes Legacy U.S. Department of Justice Matter

Read more

November 19, 2025 · 9:21 AM UTC

Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference

Read more

November 3, 2025 · 8:00 AM UTC

Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine

Read more

October 30, 2025 · 7:00 AM UTC

Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

Read more

October 28, 2025 · 10:00 AM UTC

Indivior to Participate in the Stifel 2025 Healthcare Conference

Read more